SCHEMBL5142991

SCHEMBL5142991

COc1[c]c2cc(Br)ccc2cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB4A P04350 3/20 0.36
TUBB P07437 3/20 0.36
TUBA3C P0DPH7 3/20 0.36
TUBA1B P68363 3/20 0.36
TUBA4A P68366 3/20 0.36
TUBB4B P68371 3/20 0.36
TUBB3 Q13509 3/20 0.36
TUBB2A Q13885 3/20 0.36
TUBB8 Q3ZCM7 3/20 0.36
TUBA3E Q6PEY2 3/20 0.36
TUBA1A Q71U36 3/20 0.36
TUBA1C Q9BQE3 3/20 0.36
TUBB6 Q9BUF5 3/20 0.36
TUBB2B Q9BVA1 3/20 0.36
TUBB1 Q9H4B7 3/20 0.36
CYP2A6 P11509 1/20 0.34
POLB P06746 1/20 0.33
KDM4E B2RXH2 2/20 0.32
MEN1 O00255 2/20 0.32
ALDH1A1 P00352 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15564239 0.87 CYP2A6 (0.38) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL11361135 0.78 CYP2A6 (0.47) CYP2A6POLBKDM4EMEN1ALDH1A1
SCHEMBL14472601 0.76 AHR (0.33) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL64917 0.74 CYP1A2 (0.40) CYP2A6POLBKDM4EALDH1A1MAPT
SCHEMBL5227738 0.74 CYP1A2 (0.40) CYP2A6POLBKDM4EALDH1A1MAPT
SCHEMBL357540 0.73 CYP2A6 (0.45) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL27896427 0.72 CYP1A2 (0.35) CYP2A6KDM4EALDH1A1MAPTSMN1; SMN2
SCHEMBL5144913 0.69 CYP2A6 (0.50) CYP2A6POLBKDM4EMEN1KMT2A
SCHEMBL27802205 0.68 CYP2A6 (0.34) CYP2A6KDM4EMEN1ALDH1A1MAPT
SCHEMBL27822798 0.68 CYP2A6 (0.34) CYP2A6POLBKDM4EMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1285914-B1 Nr1h4 nuclear receptor binding compounds PHENEX PHARMACEUTICALS AG (DE) 2007-12-19 EP disclosed
EP-1423370-A4 FXR NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS PHENEX PHARMACEUTICALS AG (DE) 2007-04-18 EP disclosed
EP-1423113-A4 NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS PHENEX PHARMACEUTICALS AG (DE) 2007-04-18 EP disclosed
EP-1423111-A4 FXR NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS PHENEX PHARMACEUTICALS AG (DE) 2007-04-18 EP disclosed
US-20070010562-A1 Nr1h4 nuclear receptor binding compounds PHENEX PHARMACEUTICALS AG (DE) 2007-01-11 US disclosed
US-7098336-B2 FXR NR1H4 nuclear receptor binding compounds PHENEX PHARMACEUTICALS AG (DE) 2006-08-29 US disclosed
US-20060148876-A1 Nr3b1 nuclear receptor binding 3-substituted pyrazoles PHENEX PHARMACEUTICALS AG (DE) 2006-07-06 US disclosed
EP-1536799-B1 NOVEL 2-AMINO-4-OXOQUINAZOLONES AS LXR NUCLEAR RECEPTOR BINDING COMPOUNDS WITH PARTIAL AGONISTIC PROPERTIES PHENEX PHARMACEUTICALS AG (DE) 2006-05-10 EP disclosed
US-7034046-B2 NR1H4 nuclear receptor binding compounds PHENEX PHARMACEUTICALS AG (DE) 2006-04-25 US disclosed
WO-2006002022-A2 COMPOSITIONS AND METHODS USEFUL FOR THE TREATMENT OF HYPERGLYCEMIA IMMUSOL INCORPORATED (US) 2006-01-05 WO disclosed
US-5925527-A SCREENING NEW PHARMACEUTICALS TREGA BIOSCIENCES, INC. (US) 1999-07-20 US disclosed
US-5916899-A SOLID PHASE SYNTHESIS, REACTING PROTECTED AMINO ACID WITH SOLID SUPPORT; FORMING IMINE BY REACTION WITH ALDEHYDE, CYCLIZATION WITH ANHYDRIDE, CLEAVAGE AND DEPROTECTION. TREGA BIOSCIENCES, INC. (US) 1999-06-29 US disclosed
EP-0923734-A1 QUINOLINE DERIVATIVES AND QUINOLINE COMBINATORIAL LIBRARIES Trega Biosciences, Inc. (US) 1999-06-23 EP disclosed
US-5874443-A BIOSYNTHESIS TREGA BIOSCIENCES, INC. (US) 1999-02-23 US disclosed
US-5840500-A OPIOD RECEPTORS AS ANALGESICS AND CENTRALLY ACTING PAIN KILLERS TREGA BIOSCIENCES, INC. (US) 1998-11-24 US disclosed
EP-0863877-A1 ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) 1998-09-16 EP disclosed
WO-1998034115-A1 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES TREGA BIOSCIENCES, INC. (US) 1998-08-06 WO disclosed
WO-1998002741-A9 QUINOLINE DERIVATIVES AND QUINOLINE COMBINATORIAL LIBRARIES 1998-05-22 WO disclosed
WO-1998002741-A1 QUINOLINE DERIVATIVES AND QUINOLINE COMBINATORIAL LIBRARIES TREGA BIOSCIENCES, INC. (US) 1998-01-22 WO disclosed
WO-1997016428-A1 ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) 1997-05-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010562-A1 Nr1h4 nuclear receptor binding compounds NR1H4, NR1H2, NR1H3 TUBB4A 2599/4885TUBB 3226/4885TUBA3C 4400/4885
US-20060148876-A1 Nr3b1 nuclear receptor binding 3-substituted pyrazoles NR0B1, NR0B2, NR4A3 TUBB4A 1469/4885TUBB 1409/4885TUBA3C 2159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.